Literature DB >> 19158308

Impaired synaptic vesicle release and immaturity of neuromuscular junctions in spinal muscular atrophy mice.

Lingling Kong1, Xueyong Wang, Dong W Choe, Michelle Polley, Barrington G Burnett, Marta Bosch-Marcé, John W Griffin, Mark M Rich, Charlotte J Sumner.   

Abstract

The motor neuron disease spinal muscular atrophy (SMA) causes profound muscle weakness that most often leads to early death. At autopsy, SMA is characterized by loss of motor neurons and muscle atrophy, but the initial cellular events that precipitate motor unit dysfunction and loss remain poorly characterized. Here, we examined the function and corresponding structure of neuromuscular junction (NMJ) synapses in a mouse model of severe SMA (hSMN2/delta7SMN/mSmn-/-). Surprisingly, most SMA NMJs remained innervated even late in the disease course; however they showed abnormal synaptic transmission. There was a two-fold reduction in the amplitudes of the evoked endplate currents (EPCs), but normal spontaneous miniature EPC (MEPC) amplitudes. These features in combination indicate reduced quantal content. SMA NMJs also demonstrated increased facilitation suggesting a reduced probability of vesicle release. By electron microscopy, we found a decreased density of synaptic vesicles that is likely to contribute to the reduced release probability. In addition to presynaptic defects, there were postsynaptic abnormalities. EPC and MEPC decay time constants were prolonged because of a slowed switch from the fetal acetylcholine receptor (AChR) gamma-subunit to the adult epsilon-subunit. There was also reduced size of AChR clusters and small myofibers, which expressed an immature pattern of myosin heavy chains. Together these results indicate that impaired synaptic vesicle release at NMJs in severe SMA is likely to contribute to failed postnatal maturation of motor units and muscle weakness.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19158308      PMCID: PMC2746673          DOI: 10.1523/JNEUROSCI.4434-08.2009

Source DB:  PubMed          Journal:  J Neurosci        ISSN: 0270-6474            Impact factor:   6.167


  46 in total

1.  Reduced neuromuscular quantal content with normal synaptic release time course and depression in canine motor neuron disease.

Authors:  Mark M Rich; Xueyong Wang; Timothy C Cope; Martin J Pinter
Journal:  J Neurophysiol       Date:  2002-12       Impact factor: 2.714

2.  Roles of neurotransmitter in synapse formation: development of neuromuscular junctions lacking choline acetyltransferase.

Authors:  Thomas Misgeld; Robert W Burgess; Renate M Lewis; Jeanette M Cunningham; Jeff W Lichtman; Joshua R Sanes
Journal:  Neuron       Date:  2002-11-14       Impact factor: 17.173

3.  Voltage clamping of unparalysed cut rat diaphragm for study of transmitter release.

Authors:  M I Glavinović
Journal:  J Physiol       Date:  1979-05       Impact factor: 5.182

4.  Functional motor unit failure precedes neuromuscular degeneration in canine motor neuron disease.

Authors:  R J Balice-Gordon; D B Smith; J Goldman; L C Cork; A Shirley; T C Cope; M J Pinter
Journal:  Ann Neurol       Date:  2000-05       Impact factor: 10.422

5.  Change in synaptic channel gating during neuromuscular development.

Authors:  B Sakmann; H R Brenner
Journal:  Nature       Date:  1978-11-23       Impact factor: 49.962

6.  Early and selective loss of neuromuscular synapse subtypes with low sprouting competence in motoneuron diseases.

Authors:  D Frey; C Schneider; L Xu; J Borg; W Spooren; P Caroni
Journal:  J Neurosci       Date:  2000-04-01       Impact factor: 6.167

7.  Neurofilament accumulation at the motor endplate and lack of axonal sprouting in a spinal muscular atrophy mouse model.

Authors:  Carmen Cifuentes-Diaz; Sophie Nicole; Maria E Velasco; Christophe Borra-Cebrian; Cristina Panozzo; Tony Frugier; Gaelle Millet; Natacha Roblot; Vandana Joshi; Judith Melki
Journal:  Hum Mol Genet       Date:  2002-06-01       Impact factor: 6.150

8.  Passive transfer of Lambert-Eaton syndrome to mice induces dihydropyridine sensitivity of neuromuscular transmission.

Authors:  Michael T Flink; William D Atchison
Journal:  J Physiol       Date:  2002-09-01       Impact factor: 5.182

9.  Amyotrophic lateral sclerosis is a distal axonopathy: evidence in mice and man.

Authors:  Lindsey R Fischer; Deborah G Culver; Philip Tennant; Albert A Davis; Minsheng Wang; Amilcar Castellano-Sanchez; Jaffar Khan; Meraida A Polak; Jonathan D Glass
Journal:  Exp Neurol       Date:  2004-02       Impact factor: 5.330

10.  Smn, the spinal muscular atrophy-determining gene product, modulates axon growth and localization of beta-actin mRNA in growth cones of motoneurons.

Authors:  Wilfried Rossoll; Sibylle Jablonka; Catia Andreassi; Ann-Kathrin Kröning; Kathrin Karle; Umrao R Monani; Michael Sendtner
Journal:  J Cell Biol       Date:  2003-11-17       Impact factor: 10.539

View more
  195 in total

1.  IPLEX administration improves motor neuron survival and ameliorates motor functions in a severe mouse model of spinal muscular atrophy.

Authors:  Michela Murdocca; Arianna Malgieri; Andrea Luchetti; Luciano Saieva; Gabriella Dobrowolny; Elvira de Leonibus; Antonio Filareto; Maria Chiara Quitadamo; Giuseppe Novelli; Antonio Musarò; Federica Sangiuolo
Journal:  Mol Med       Date:  2012-09-25       Impact factor: 6.354

2.  Motor neuron rescue in spinal muscular atrophy mice demonstrates that sensory-motor defects are a consequence, not a cause, of motor neuron dysfunction.

Authors:  Rocky G Gogliotti; Katharina A Quinlan; Courtenay B Barlow; Christopher R Heier; C J Heckman; Christine J Didonato
Journal:  J Neurosci       Date:  2012-03-14       Impact factor: 6.167

Review 3.  Spinal muscular atrophy: new and emerging insights from model mice.

Authors:  Gyu-Hwan Park; Shingo Kariya; Umrao R Monani
Journal:  Curr Neurol Neurosci Rep       Date:  2010-03       Impact factor: 5.081

4.  Alpha-synuclein loss in spinal muscular atrophy.

Authors:  Gyula Acsadi; Xingli Li; Kelley J Murphy; Kathryn J Swoboda; Graham C Parker
Journal:  J Mol Neurosci       Date:  2010-07-17       Impact factor: 3.444

5.  Survival motor neuron protein in motor neurons determines synaptic integrity in spinal muscular atrophy.

Authors:  Tara L Martinez; Lingling Kong; Xueyong Wang; Melissa A Osborne; Melissa E Crowder; James P Van Meerbeke; Xixi Xu; Crystal Davis; Joe Wooley; David J Goldhamer; Cathleen M Lutz; Mark M Rich; Charlotte J Sumner
Journal:  J Neurosci       Date:  2012-06-20       Impact factor: 6.167

6.  Non-aggregating tau phosphorylation by cyclin-dependent kinase 5 contributes to motor neuron degeneration in spinal muscular atrophy.

Authors:  Nimrod Miller; Zhihua Feng; Brittany M Edens; Ben Yang; Han Shi; Christie C Sze; Benjamin Taige Hong; Susan C Su; Jorge A Cantu; Jacek Topczewski; Thomas O Crawford; Chien-Ping Ko; Charlotte J Sumner; Long Ma; Yong-Chao Ma
Journal:  J Neurosci       Date:  2015-04-15       Impact factor: 6.167

Review 7.  Mechanistic principles of antisense targets for the treatment of spinal muscular atrophy.

Authors:  Natalia N Singh; Brian M Lee; Christine J DiDonato; Ravindra N Singh
Journal:  Future Med Chem       Date:  2015-09-18       Impact factor: 3.808

8.  Temporal requirement for SMN in motoneuron development.

Authors:  Le T Hao; Phan Q Duy; James D Jontes; Marc Wolman; Michael Granato; Christine E Beattie
Journal:  Hum Mol Genet       Date:  2013-03-03       Impact factor: 6.150

9.  Altered intracellular Ca2+ homeostasis in nerve terminals of severe spinal muscular atrophy mice.

Authors:  Rocío Ruiz; Juan José Casañas; Laura Torres-Benito; Raquel Cano; Lucía Tabares
Journal:  J Neurosci       Date:  2010-01-20       Impact factor: 6.167

10.  Systemic peptide-mediated oligonucleotide therapy improves long-term survival in spinal muscular atrophy.

Authors:  Suzan M Hammond; Gareth Hazell; Fazel Shabanpoor; Amer F Saleh; Melissa Bowerman; James N Sleigh; Katharina E Meijboom; Haiyan Zhou; Francesco Muntoni; Kevin Talbot; Michael J Gait; Matthew J A Wood
Journal:  Proc Natl Acad Sci U S A       Date:  2016-09-12       Impact factor: 11.205

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.